ASH13: The ENESTnd trial update
December 8, 2013|Oncology Practice
Author and Disclosure Information
Updated results from the ENESTnd trial at 5 years showed nilotinib sustained efficacy, compared with imatinib, in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Dr. Giuseppe Saglio puts these 5-year data into perspective.